[Effect of aprotinin in acute myocardial infarction (clinical double-bind study (author's transl)].
In a double-bind study 164 patients with acute myocardial infarction, admitted to an intensive-care unit within 72 hours of infarction, were randomly treated for three days either with aprotinin (Trasylol-82 persons) or placebo (82 persons). Retrospective analysis proved both patient groups to have been comparable in all other respects. There was no definite influence on the course of the infarction, haemodynamic changes, arrythmias or mortality rate. Trasylol thus has no therapeutic importance in the treatment of acute myocardial infarction.
D000208:Acute Disease; D000328:Adult; D000368:Aged; D007611:Aprotinin / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004562:Electrocardiography; D005260:Female; D006333:Heart Failure / Q000209:etiology; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D010493:Pericarditis / Q000209:etiology; D011379:Prognosis; D011655:Pulmonary Embolism / Q000209:etiology; D012770:Shock, Cardiogenic / Q000209:etiology
D007611:Aprotinin
Zur Wirkung von Aprotinin beim akuten Myokardinfarkt. Eine klinische Doppelblindstudie